SPRO Key Statistics, Chart & Performance
The current stock price of SPRO is 2.31 USD. In the past month the price decreased by -8.76%. In the past year, price increased by 179.81%.
SPRO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to SPRO. When comparing the yearly performance of all stocks, SPRO is one of the better performing stocks in the market, outperforming 96.43% of all stocks.
SPRO Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SPRO. While SPRO seems to be doing ok healthwise, there are quite some concerns on its profitability.
SPRO Financial Highlights
Over the last trailing twelve months SPRO reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS decreased by -1228.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -80.92% | ||
| ROE | -165.46% | ||
| Debt/Equity | 0 |
SPRO Forecast & Estimates
6 analysts have analysed SPRO and the average price target is 4.08 USD. This implies a price increase of 76.62% is expected in the next year compared to the current price of 2.31.
For the next year, analysts expect an EPS growth of 91.97% and a revenue growth -34.56% for SPRO
SPRO Ownership
SPRO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.05 | 383.716B | ||
| AMGN | AMGEN INC | 16.28 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 16.77 | 181.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.64 | 119.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.65 | 81.459B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.14 | 46.497B | ||
| INSM | INSMED INC | N/A | 32.511B | ||
| NTRA | NATERA INC | N/A | 28.376B | ||
| BIIB | BIOGEN INC | 11.98 | 27.206B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.27 | 20.78B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SPRO
Company Profile
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company is headquartered in Cambridge, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Company Info
SPERO THERAPEUTICS INC
675 Massachusetts Ave Ste 14
Cambridge MASSACHUSETTS 02139 US
CEO: Ankit Mahadevia
Employees: 32
Phone: 18572421600
SPERO THERAPEUTICS INC / SPRO FAQ
What does SPERO THERAPEUTICS INC do?
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company is headquartered in Cambridge, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Can you provide the latest stock price for SPERO THERAPEUTICS INC?
The current stock price of SPRO is 2.31 USD. The price increased by 0.87% in the last trading session.
Does SPRO stock pay dividends?
SPRO does not pay a dividend.
How is the ChartMill rating for SPERO THERAPEUTICS INC?
SPRO has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the sector and industry classification for SPERO THERAPEUTICS INC?
SPERO THERAPEUTICS INC (SPRO) operates in the Health Care sector and the Biotechnology industry.
Can you provide the upcoming earnings date for SPERO THERAPEUTICS INC?
SPERO THERAPEUTICS INC (SPRO) will report earnings on 2026-03-25, after the market close.
What is the Short Interest ratio of SPERO THERAPEUTICS INC (SPRO) stock?
The outstanding short interest for SPERO THERAPEUTICS INC (SPRO) is 2.39% of its float.